Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Döhner H, Döhner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG.

Cancer Cell. 2007 Dec;12(6):501-13.

2.
3.

Emerging Flt3 kinase inhibitors in the treatment of leukaemia.

Tickenbrock L, Müller-Tidow C, Berdel WE, Serve H.

Expert Opin Emerg Drugs. 2006 Mar;11(1):153-65. Review.

PMID:
16503833
4.

From kinases to cancer: leakiness, loss of autoinhibition and leukemia.

Reindl C, Spiekermann K.

Cell Cycle. 2006 Mar;5(6):599-602. Review.

PMID:
16582613
5.

Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.

Masson K, Rönnstrand L.

Cell Signal. 2009 Dec;21(12):1717-26. doi: 10.1016/j.cellsig.2009.06.002. Review.

PMID:
19540337
6.

Structural and functional alterations of FLT3 in acute myeloid leukemia.

Meshinchi S, Appelbaum FR.

Clin Cancer Res. 2009 Jul 1;15(13):4263-9. doi: 10.1158/1078-0432.CCR-08-1123. Review.

7.

FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.

Langdon WY.

Crit Rev Oncog. 2012;17(2):199-209. Review.

PMID:
22471708
8.
9.

Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model.

Chan PM.

Protein Cell. 2011 Feb;2(2):108-15. doi: 10.1007/s13238-011-1020-7. Review.

Items per page

Supplemental Content

Support Center